Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +44.71%
#3 ADO Protocol ADO Protocol +38.80%
#4 Prom Prom +34.38%
#5 Pons Pons +32.43%
#6 StonkBroker StonkBroker +31.49%
#7 TENDIES TENDIES +27.68%
#8 Collector Crypt Collector Crypt +27.15%
#9 龙虾 (Lobster) 龙虾 (Lobster) +21.71%
#10 Cysic Cysic +20.11%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Gubra A/S Gubra A/S

Gubra A/S

GUBRA
Rank in Stocks #9438
Gubra A/S is a biotechnology firm engaged in two core activities: offering... Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
Share Price
$61.73
Last synced: 2026-08-28
Market Cap
$1.01B
Change (1 day)
-1.02%
Change (1 year)
5.10%
Country
DK
Trade Gubra A/S (GUBRA)

Category

Healthcare
Revenue for Gubra A/S (GUBRA)
Revenue in Aug 2026 TTM: 0
According to Gubra A/S latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gubra A/S from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH